Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224678 · ClinicalTrials.gov registry record · Phase 3
Vitamin D and Breast Cancer Biomarkers in Female Patients
A Phase 3 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT01224678: Completed Phase 3 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT01224678 is a Phase 3 study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 300 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01224678, a Phase 3 study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Vitamin D may help prevent breast cancer. PURPOSE: This randomized clinical trial is studying vitamin D and breast cancer biomarkers in female patients.
Primary Outcome
To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women. The percent change in breast density will be reported here.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT vitamin D
Study Locations (20)
California
- Contra Costa Regional Medical Center - Martinez
- Camino Medical Group - Treatment Center - Mountain View
- El Camino Hospital Cancer Center - Mountain View
- Bay Area Breast Surgeons, Incorporated - Oakland
- CCOP - Bay Area Tumor Institute - Oakland
- Larry G Strieff MD Medical Corporation - Oakland
- Tom K Lee, Incorporated - Oakland
- Palo Alto Medical Foundation - Palo Alto
- - Pismo Beach
- Doctors Medical Center - San Pablo Campus - San Pablo
Florida
- Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital - Fort Lauderdale
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center - Jupiter
- CCOP - Mount Sinai Medical Center - Miami Beach
- Florida Hospital Cancer Institute at Florida Hospital Orlando - Orlando
Illinois
- Illinois CancerCare - Bloomington - Bloomington
- St. Joseph Medical Center - Bloomington
- Illinois CancerCare - Canton - Canton
- University of Chicago Cancer Research Center - Chicago
Alabama
- Regional Medical Center - Anniston
Connecticut
- Bendheim Cancer Center at Greenwich Hospital - Greenwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT01224678 record still lists
NCT01224678 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01224678 names 20 study sites across 5 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT01224678 about?
NCT01224678 is a clinical study titled "Vitamin D and Breast Cancer Biomarkers in Female Patients". RATIONALE: Vitamin D may help prevent breast cancer. PURPOSE: This randomized clinical trial is studying vitamin D and breast cancer biomarkers in female patients.
What is the current status of trial NCT01224678?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2010-10. Estimated completion is 2014-12.
What conditions does trial NCT01224678 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01224678?
The interventions under investigation include: placebo (OTHER), vitamin D (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01224678?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01224678 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01224678's enrollment target sits among peer trials
300 277th of 1224 higher than 938 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia